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Quiz
A 70-year old woman presented to the emergency 
department with fatigue and prosyncopal episodes 
commencing two days ago. The ECG recording revealed 
2:1 atrioventricular block with periods of 3:2 Wenckebach 
conduction. The intracardiac electrograms during 
spontaneous sinus rhythm and atrial pacing are 
demonstrated below.
Figure 1. Atrial pacing. His bundle recording is marked 
with a red dot.
Figure 2. Recording during sinus rhythm. His bundle 
recording is marked with a red dot.
What is your diagnosis?
Answer to the quiz
Usually, Wenckebach conduction implies that the site of 
the disturbance is above the His bundle, namely in the 
atrioventricular node. In most circumstances this kind of 
conduction abnormality does not mandates the 
implantation of a permanent pacemaker. However in this 
specific case, we can see that during atril pacing which 
reproduces 2:1 block, the conduction is halted below the 
His bundle as the recording of both A (atrial) and H (His) 
electrograms suggest (figure 1). During sinus rhythm, 
Wenckebach pattern is apparent and the second beat is 
conducted with abberancy and a prolonged HV interval
(figure 2). The third atrial beat is blocked below His 
bundle. In this example we have an infra-Hisian 
Wenckebach conduction pattern which obliges the need of 
a permanent pacemaker. 
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The ACC Annual Congress is slated for April 3-5, 
2011 in New Orleans 
 
The HRS Annual Meeting is scheduled for May 4-7, 
2011 in San Francisco 
 
Euro-PCR will take place in Paris on May 17-20, 
2011 
 
The ESC Annual Congress is slated for 27-
31/8/2011 in Paris 
 
The TCT Annual Conference will be held in San 
Francisco 7-11/11/2011  
 
The AHA Annual Scientific Sessions are scheduled 
for 12-16/11/2011 in Orlando 
 
Athens Cardiology Update 2012 is slated for April 
5-7, 2012 
 
Local Atrial Inflammation Present in Paroxysmal AF
 
Atrial biopsies were obtained from 70 patients (age 60 
± 12 years, 49 males) undergoing radiofrequency catheter
ablation for AF and 10 patients with Wolff-Parkinson-
White syndrome, all undergoing trans-septal puncture.
Biopsies were obtained by washing the dilator and needle 
used for trans-septal puncture with 20 mL sterile 
phosphate-buffered saline, and formalin fixed specimen 
were examined by immunohistochemistry for the presence 
of intracytoplasmic C-reactive protein. C-reactive protein
was revealed in isolated atrial cardiomyocytes in 11 (73%) 
of 15 patients with paroxysmal AF as compared with 2 
(25%) of 8 patients with persistent AF (P= 0.02). This 
technique for obrtaining biopsy specimen was safe and 
feasible. In this study, local atrial inflammation as 
assessed by C-reactive protein present in atrial myocytes,
is more likely involved in paroxysmal rather than in 
persistent AF (Narducci ML et al, Europace. 2011 Mar 
29. [Epub ahead of print])
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Are all statins the same? Focus on the efficacy and 
tolerability of pitavastatin
Pitavastatin is the latest addition to the statin family 
which undergoes minimal metabolism by cytochrome P450
(CYP) enzymes and, thus, has a low propensity for 
interactions with drugs metabolized by CYP enzymes. It 
displays potent and consistent beneficial effects on lipids 
and has a favourable side effect profile with increases in 
plasma CK levels in <5% of patients and the incidence of 
myopathy or rhabdomyolysis being extremely low. 
Interestingly, in addition to its lowering effect on total and 
LDL cholesterol and triglycerides (21-32%, 30-45%, and 
10-30%, respectively), it also exhibits some potential for 
increasing HDL cholesterol (mean increase 3-10%). In 
comparison to atorvastatin, pitavastatin showed similar 
efficacy in lipid-lowering ability with a trend towards 
HDL increase. Moreover, it shows beneficial effects 
regarding the cardiovascular risk independently of its 
effect on lipid levels. In the JAPAN-ACS study, it was 
non-inferior to atorvastatin at reducing plaque volume in
patients with ACS undergoing PCI. It also exerts 
pleiotropic effects as revealed by improvements in markers 
of inflammation, oxidative stress, and renal function that 
have been demonstrated in a number of small studies (da 
Silva PM. Am J Cardiovasc Drugs 2011;11:93-107).
Radiofrequency catheter ablation of ventricular 
tachycardia in arrhythmogenic right ventricular 
dysplasia using non-contact electroanatomical
mapping: single-center experience with follow-up up to 
median of 30 months
The efficacy of radiofrequency ablation (RFA) of 
ventricular tachycardia (VT) was evaluated in 15 patients 
(44Ԝ±Ԝ15 years) with arrhythmogenic right ventricular
dysplasia (ARVD), using non-contact electro-anatomic 
mapping. Twenty-two of the 25 inducible VTs mapped, 
were successfully ablated. In 13 out of 15 patients, all the 
clinical and inducible VTs were ablated. All patients 
remained asymptomatic at 25Ԝ±Ԝ16 months (2-52 months)
although antiarrhythmic medications were discontinued 
after 6 months. Two patients had recurrence of non-
clinical VT on follow-up. In conclusion, a majority of 
induced VT in patients with ARVD can be successfully 
mapped and ablated using the non-contact Ensite Array 
Mapping system with good long-term VT-free outcome. 
Ablation can be a useful adjunct to AICD implantation in 
such patients (Nair M et al, J Interv Card Electrophysiol. 
2011 Mar 25. [Epub ahead of print])
Intracoronary levosimendan prevents myocardial 
ischemic damages and activates survival signaling 
through ATP-sensitive potassium channel and nitric 
oxide 
The cardiac effects of different doses of intracoronary
levosimendan on ischemia/reperfusion injuries, and the 
involvement of K(ATP) channels and nitric oxide (NO) 
were examined in 56 pigs. In 21 pigs, 1.5, 5 & 12 ȝg/min 
levosimendan was infused over 15 min into the coronary 
artery at the onset of 1 h reperfusion following 2-h
ischemia and the effects on cardiac function, infarcted 
area, and on apoptosis/autophagy were examined. The 
activation of Akt and extracellular receptor kinase (ERK) 
was also analyzed. The findings were compared with those 
obtained in 14 pigs where the highest dose levosimendan
was infused after glibenclamide and l-nitro-arginine methyl
ester (l-NAME). Intracoronary levosimendan caused a 
dose dependent increase of segmental shortening, 
dP/dt(max) and cardiac output from values measured at 
the end of ischemia. Notably, these beneficial effects were
still evident albeit somewhat attenuated at the end of 
reperfusion. When doses of 5 and 12 ȝg min(-1) 
levosimendan were used, a reduction of infarcted area to 
about 69% and 67% of area at risk was observed, and was 
significantly different from that of about 79% measured in 
control animals. In addition, the inhibition of apoptosis 
and activation of autophagy and a dose-related increase of 
the level of phosphorylation of ERK and Akt were 
observed. These responses were completely prevented by 
glibenclamide and significantly reduced by l-NAME. In 
conclusion intracoronary levosimendan seems to reduce 
cell death induced by ischemia/reperfusion in a dose-
dependent manner and activates survival signaling through 
K(ATP) channel opening and NO, in  an animal model of 
cardiac ischemia/reperfusion (Caimmi PP et al. Eur J 
Cardiothorac Surg. 2011 ;39:e59-67. Epub 2011 Jan 17)
Genetic mechanisms mediating atherosclerosis 
susceptibility at the chromosome 9p21 locus
Recent genome-wide association studies have 
demonstrated that common genetic variants in a region of 
chromosome 9p21 confer risk of coronary artery disease 
(CAD) and other atherosclerotic conditions. The absolute 
increase in risk is small (some 20-30% increase in risk of 
CAD per copy of the deleterious alleles), but the common 
occurrence of the variants may pose a substantial risk in a 
general population scale. So far, no association between 
risk variants and both "classical" and "emerging" 
atherosclerotic risk factors has been established, indicating 
that the effect of the 9p21 locus on atherosclerotic risk is 
mediated via a hitherto unknown pathway which could 
represent a possible therapeutic target (Cunnington MS, 
Keavney B. Curr Atheroscler Rep 2011;13:193-201)
